Débora Barbosa Vendramini Costa

Débora Barbosa Vendramini Costa

Auto-generated profile, based on publicly available information

Débora Barbosa Vendramini Costa

Henry Ford Health System 12 Detroit, Michigan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2012 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
DVD. B. Vendramini-Costa
D. B. Vendramini-Costa
JCJ. E. Carvalho
J. E. Carvalho
Inflammation is part of the body's response to internal and external environmental stimuli that normally eliminate the aggressor agent and restore the tissue physiology. However, when it becomes chronic, it can cause several pathologies such as cardiovascular, diabetes, rheumatoid arthritis, Alzheimer's autoimmune diseases and cancer. Currently, epidemiological data indicate that over 25% of all cancers are related to chronic infections and other types of unresolved inflammation. Further evidence of this relationship is the fact that prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk to developing many types of cancers. Some randomized trials have shown that NSAIDs have protective action against colon adenomas, breast, prostate, and lung cancers. The inflammation present on tumor microenvironment is characterized by leukocyte infiltration, ranging in size, distribution and composition, as: tumor-associated macrophages (TAM), mast cells, dendritic cells, natural killer (NK) cells, neutrophils, eosinophils and lymphocytes. These cells produce a variety of cytotoxic mediators such as reactive oxygen and nitrogen species (ROS and RNS respectively), serine and cysteine proteases, membrane perforating agents, matrix metalloproteinase (MMP), tumor necrosis factor α (TNFα), interleukins (IL-1, IL-6, IL-8), interferons (IFNs) and enzymes, as cyclooxygenase-2 (COX-2), lipooxygenase-5 (LOX-5) and phospholipase A2 (PLA2), which activate or are activated by transcription factors as nuclear factor κB (NF-κB) and signal transducers and activators of transcription-3 (STAT3). Initially this paper will briefly review the main mediators present on tumor microenvironment, addressing the cytokines, chemokines, transcription factors, eicosanoid, and kinins and later, will present an overview of the role of inflammation in the different steps of carcinogenesis.

30 October 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
RFRalph Francescone
Ralph Francescone
DVDébora Barbosa Vendramini-Costa
Débora Barbosa Vendramini-Costa
JFJanusz Franco-Barraza
Janusz Franco-Barraza
JWJessica Wagner
Jessica Wagner
AMAlexander Muir
Alexander Muir
ECEdna Cukierman
Edna Cukierman
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate and lacks effective therapeutics. Therefore, it is of paramount importance to identify new targets. Using multiplex data from patient tissue, three-dimensional coculturing in vitro assays, and orthotopic murine models, we identified Netrin G1 (NetG1) as a promoter of PDAC tumorigenesis. We found that NetG1+ cancer-associated fibroblasts (CAF) support PDAC survival, through a NetG1-mediated effect on glutamate/glutamine metabolism. Also, NetG1+ CAFs are intrinsically immunosuppressive and inhibit natural killer cell–mediated killing of tumor cells. These protumor functions are controlled by a signaling circuit downstream of NetG1, which is comprised of AKT/4E-BP1, p38/FRA1, vesicular glutamate transporter 1, and glutamine synthetase. Finally, blocking NetG1 with a neutralizing antibody stunts in vivo tumorigenesis, suggesting NetG1 as potential target in PDAC.Significance: This study demonstrates the feasibility of targeting a fibroblastic protein, NetG1, which can limit PDAC tumorigenesis in vivo by reverting the protumorigenic properties of CAFs. Moreover, inhibition of metabolic proteins in CAFs altered their immunosuppressive capacity, linking metabolism with immunomodulatory function.See related commentary by Sherman, p. 230.This article is highlighted in the In This Issue feature, p. 211

1 October 2017 in Food Chemistry
Verified
Journal Article
Closed access
SASheila Cristina Oliveira Alves
Sheila Cristina Oliveira Alves
DVDébora Barbosa Vendramini-Costa
Débora Barbosa Vendramini-Costa
CCCinthia Baú Betim Cazarin
Cinthia Baú Betim Cazarin
MJMário Roberto Maróstica Junior
Mário Roberto Maróstica Junior
JFJoão Pedro Borges Ferreira
João Pedro Borges Ferreira
MBMaria Bronze
Maria Bronze

5 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
ILIan M. Loveless
Ian M. Loveless
SKSamantha B. Kemp
Samantha B. Kemp
KHKailee M. Hartway
Kailee M. Hartway
JMJacob T. Mitchell
Jacob T. Mitchell
YWYuesong Wu
Yuesong Wu
NSNina G. Steele
Nina G. Steele
Purpose: Pancreatic ductal adenocarcinoma (PDAC) patients with tumors enriched for the basal-like molecular subtype exhibit enhanced resistance to standard-of-care treatments and have significantly worse overall survival compared with patients with classic subtype–enriched tumors. It is important to develop genomic resources, enabling identification of novel putative targets in a statistically rigorous manner. Experimental Design: We compiled a single-cell RNA sequencing (scRNA-seq) atlas of the human pancreas with 229 patient samples aggregated from publicly available raw data. We mapped cell type–specific scRNA-seq gene signatures in bulk RNA-seq (n = 744) and spatial transcriptomics (ST; n = 22) and performed validation using multiplex immunostaining. Results: Analysis of tumor cells from our scRNA-seq atlas revealed nine distinct populations, two of which aligned with the basal subtype, correlating with worse overall survival in bulk RNA-seq. Deconvolution identified one of the basal populations to be the predominant tumor subtype in nondissociated ST tissues and in vitro tumor cell and patient-derived organoid lines. We discovered a novel enrichment and spatial association of CXCL10+ cancer-associated fibroblasts with basal tumor cells. We identified that besides immune cells, ductal cells also express CXCR3, the receptor for CXCL10, suggesting a relationship between these cell types in the PDAC tumor microenvironment. Conclusions: We show that our scRNA-seq atlas (700,000 cells), integrated with ST data, has increased statistical power and is a powerful resource, allowing for expansion of current subtyping paradigms in PDAC. We uncovered a novel signaling niche marked by CXCL10+ cancer-associated fibroblasts and basal tumor cells that could be explored for future targeted therapies.

1 November 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JOJamerson Ferreira de Oliveira
Jamerson Ferreira de Oliveira
ASAnekécia Lauro da Silva
Anekécia Lauro da Silva
DVDébora Barbosa Vendramini-Costa
Débora Barbosa Vendramini-Costa
CACezar Augusto da Cruz Amorim
Cezar Augusto da Cruz Amorim
JCJúlia Furtado Campos
Júlia Furtado Campos
MLMaria Do Carmo Alves De Lima
Maria Do Carmo Alves De Lima

1 August 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JOJamerson Ferreira de Oliveira
Jamerson Ferreira de Oliveira
TLTalitha Santos Lima
Talitha Santos Lima
DVDébora Barbosa Vendramini-Costa
Débora Barbosa Vendramini-Costa
SPSybelle Christianne Batista de Lacerda Pedrosa
Sybelle Christianne Batista de Lacerda Pedrosa
ELElizabeth Almeida Lafayette
Elizabeth Almeida Lafayette
MLMaria Do Carmo Alves De Lima
Maria Do Carmo Alves De Lima